날록손(Naloxone) 시장 : 강도별, 투여 경로별, 유통 채널별, 지역별

Global Naloxone Market is estimated to be valued at USD 1,483.8 Mn in 2025 and is expected to reach USD 3,005.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.6% from 2025 to 2032.

Figure. Naloxone Market Share (%), By Region 2025

Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose. It works by competitively binding to opioid receptors and reversing and blocking the effects of other opiates. Naloxone has become an integral part of emergency medical treatment for opioid overdoses. With the ongoing opioid crisis in many parts of the world, the prevalence of opioid abuse has increased massively in recent times. As a result, the need for readily available naloxone formulations has grown for emergency treatment. This factor is expected to largely influence the growth trajectory of the global naloxone market in the coming years.

Market Dynamics:

The global naloxone market is primarily driven by the rising incidence of opioid overdose cases worldwide. According to the National Institute on Drug Abuse, opioid overdose mortality rates in the U.S. increased by over 130% between 2000 and 2020. Moreover, the COVID-19 pandemic further exacerbated the impact of social isolation on psychological health and increased opioid misuse in many countries. A high demand for user-friendly naloxone delivery formulations like nasal sprays and auto-injectors from both healthcare and law enforcement agencies is fueling the market growth. However, adverse side effects associated with naloxone therapy and the availability of alternative treatment options are limiting market expansion. Ongoing R&D into the development of long-acting naloxone formulations present lucrative opportunities for key players in the future.

Key Features of the Study:

• This report provides an in-depth analysis of the global naloxone market, and provides market size (US$ MN) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global naloxone market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes EMERGENT, Indivior PLC, Akorn, Inc, Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Inc., Kaleo, Inc., Pfizer Inc., Amneal Pharmaceuticals, Viatris Inc., Somerset Pharma, LLC, Orexo AB, and UCB Pharma.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global naloxone market.

Market Segmentation

• Strength:
  • 2.0 mg/ml
  • 1 mg/ml
  • 0.4 mg/ml
  • Others
• Route of Administration:
  • Intranasal
  • Injectable
  • Intramuscular
  • Subcutaneous
  • Intravenous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • EMERGENT
  • Indivior PLC
  • Akorn, Inc
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Sandoz
  • Teva Pharmaceuticals
  • Amphastar Pharmaceuticals, Inc.
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Naloxone Market, By Strength
  • Naloxone Market, By Route of Administration
  • Naloxone Market, By Distribution Channel
  • Naloxone Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Porter's Analysis
• Industry Trends
• Key Highlights
• Epidemiology
• Reimbursement Scenario
• Regulatory Scenario
• Product Launch and Approvals
• Acquisition and Collaboration Scenario

4. Global Naloxone Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Impact of COVID-19 on the Demand and Supply of Naloxone
• Impact of COVID-19 on the Overall Healthcare Sector

5. Global Naloxone Market, By Strength, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• 2.0 mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• 1mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• 0.4 mg/ml
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)

6. Global Naloxone Market, By Route of Administration, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• Intranasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Intramuscular
• Subcutaneous
• Intravenous

7. Global Naloxone Market, By Distribution Channel, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD MN)

8. Global Naloxone Market, By Region, 2020-2032 (USD MN)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2020-2032
  • Regional Trends
• North America
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • U.S.
    • Canada
• Latin America
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country, 2020-2032 (USD MN)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Strength, 2020-2032 (USD MN)
  • Market Size and Forecast, By Route of Administration, 2020-2032 (USD MN)
  • Market Size and Forecast, By Distribution Channel, 2020-2032 (USD MN)
  • Market Size and Forecast, By Country/Region, 2020-2032 (USD MN)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

• Company Profiles
  • Viatris Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Opiant Pharmaceuticals
  • Akorn Operating Company LLC
  • Pfizer, Inc.
  • Novartis AG
  • Indivior Plc.
  • Emergent BioSolutions Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Kern Pharma, S.L.
  • Hikma Pharmaceuticals PLC
  • Mundipharma International Limited
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact